Experience with the P.A.S.-PORT venous access device in patients with gynecologic malignancies.
Experience with the P.A.S.-PORT, a peripherally implanted central venous access device, is evaluated in a retrospective review of 154 patients from July 1991 to June 1994. Blood could not be aspirated from six patients. Complications included temporary minor thrombophlebitis in seven patients (4.5%), symptomatic axillary or subclavian vein thrombosis in five patients (3.2%), clotted port in two patients (1.2%), port pocket cellulitis in two patients (1.2%), and fungal sepsis in two patients (1.2%). In six patients (3.8%) the P.A.S.-PORT had to be removed because of complications. The P.A.S.-PORT facilitated delivery of chemotherapy, parenteral nutrition, blood products, antibiotics, hydration, and blood sampling. It was demonstrated that the P.A.S.-PORT may be inserted and used with a low incidence of complications in gynecologic cancer patients.
Deppe
G
G
Department of Obstetrics and Gynecology, Wayne State University, Detroit, Michigan 48201, USA.
Kahn
M L
ML
Malviya
V K
VK
Malone
J M
JM
Christensen
C W
CW
D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D002408:Catheters, Indwelling / Q000009:adverse effects / Q000592:standards*; D002481:Cellulitis / Q000453:epidemiology / Q000209:etiology; D016889:Endometrial Neoplasms / Q000628:therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000628:therapy*; D006801:Humans; D015994:Incidence; D009181:Mycoses / Q000453:epidemiology / Q000209:etiology; D010051:Ovarian Neoplasms / Q000628:therapy; D010288:Parenteral Nutrition / Q000379:methods; D012189:Retrospective Studies; D013924:Thrombophlebitis / Q000453:epidemiology / Q000209:etiology; D002583:Uterine Cervical Neoplasms / Q000628:therapy
D000900:Anti-Bacterial Agents